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Objective. Breast irradiation, adjuvant chemotherapy, and tamoxifen are associated with an increased risk of second cancers
that may manifest decades after treatment. The objective of our study was to analyze the second cancers after breast cancer
treatment in our centre.
Materials and methods. Retrospective analysis of 46/1046 patients with breast cancer stages I and II, treated with conservative
surgery plus radiation therapy from January 1993 to December 2009 who developed second cancers after the treatment. Median
age: 60 years (37–79). 70% of the patients (pts) were stage I and 30% stage II. 25 (54%) of the pts received adjuvant chemotherapy,
medium cycle 6 (0–12), with anthracyclines (30%) and anthracycline–taxanes (13%). 89% received hormone therapy. All patients
were treated with 50Gy radiation therapy to the whole breast in 25 fractions± regional nodes with or without a boost to the
primary tumor bed of 16–20Gy in fractions 8–10. Kaplan–Meier curves have been used for the statistical analysis of survival.
Results. With a median follow-up of 135 months (39–199 months) 5% of the patients developed second cancers. The median time
until second cancer appearance was 81 months. 15 pts (33%) developed second breast cancer with a median time of 67 months
and age of 50 years and 31 pts (67%) other cancers with a median time of 83 months and age of 63 years. Endometrial cancer
was the second most frequent localization in 5 pts (11%), all of them had received adjuvant tamoxifen. Only 2 pts presented lung
cancer. The overall survival at 15 years was 69% and without signiﬁcant difference between breast and no breast second cancers
(p=0.43).
Conclusions. According to our results breast cancer was the most frequent second cancer in patients after breast cancer treatment,
followed by endometrial cancer in patients that received tamoxifen. Lung cancer was infrequent.
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Purpose. To evaluate the outcome in patients (pts) diagnosed with ductal carcinoma in situ (DCIS) of the breast treated with
conservative surgery and postoperative radiotherapy.
Materials and methods. We analyze 84 pts treated with conservative surgery and whole breast postoperative radiotherapy, 50Gy,
2Gy/fx plus electron beam boost in 21 (25%). Age, mean: 53.12 (31–72) years. Tumor size, mean: 0.7 cm (8.5–0.2 cm). Tumor margin:
clear > 5mm: 54pts (64.3%); Clear 1 – ≤5mm: 18 pts (21.4%); Involved: 6pts (7.1%); unknown: 6 (7.1%). Tumor grade I: 24 (28.6%);
grade II: 11 (13.1%); grade III 18 (21.4%); unknown: 31 (36.9%). Hormonal receptor status: Positive: 51 (60.7%); Negative 5 (6%);
Unknown 28 (33.3%). Pts were analysed in follow-up for overall survival (OS) disease-free survival (DFS), local and contralateral
breast recurrence and distant metastases.
Results. Mean follow-up: 9.96 years. Overall survival (OS): mean 17.11 years (IC95% 15.88–18.34) actuarial at 5 and 10 years: 97
and 91%, respectively. OS cancer-speciﬁc: mean 18.48 years (IC 95% 17.93–19.02) OS actuarial cancer-speciﬁc at 5 and 10 years:
98%. DFS global: mean 17.74 years (IC 95%: 16.85–18.62) actuarial at 5 and 10 years: 96% and 91%, respectively. DFS (breast): mean
18.12 years. DFS (breast) at 5 and 10 years: 94%. Two pts former diagnosed of DCIS G-III, developed visceral metastases due to
inﬁltrating ductal carcinoma of breast (IDC) and died. There were 4 breast recurrences: 1 pt suffered from ipsilateral (IDC) not in
the same quadrant. 1 pt suffered from contralateral (DCIS) 2 pts developed ipsilateral DCIS recurrence. Mean time to recurrence:
7.3 years. All ipsilateral breast recurrences were salvaged with mastectomy. All women with breast recurrence are free of disease.
Conclusion. Although prognosis of DCIS of breast is excellent and its mortality is virtually zero some high grade DCIS could be
misdiagnosed, IDC should be ruled out carefully.
http://dx.doi.org/10.1016/j.rpor.2013.03.113
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Introduction. Breast cancer is the most frequent in women. Rates of survival and local control in early stages of breast cancer are
excellent thanks to combination therapies.
Objective. To analyse retrospectively the survival and local control of diagnosed breast carcinoma patients treated with conser-
vative surgery and adjuvant radiotherapy.
Methods. From January 1997 to December 2000, 292 women with stages 0–III breast cancer were treated with conservative
surgery±adjuvant chemotherapy± radiotherapy±adjuvant hormonal therapy in HUA-Txagorritxu. 75 of them were excluded
